


Troriluzole

Chemical Properties

CAS No. :	1926203-09-9
Formula:	C ₁₅ H ₁₆ F ₃ N ₅ O ₄ S
Molecular Weight:	419.38
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Troriluzole is an orally active glutamate modulator with anticancer activity. Troriluzole enhances the expression of excitatory amino acid transporters located in glial cells and is used in the study of spinocerebellar ataxia, Alzheimer's disease, and generalized anxiety disorder (GAD).
Targets(IC50)	Others, GluR, transporter
In vitro	Troriluzole is an EAAT2 modulator, NMDA receptor antagonist, and Nav1.5 blocker, commonly used in research on neurological disorders such as obsessive-compulsive disorder[1].

Solubility Information

Solubility	DMSO: 30 mg/mL (71.53 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.77 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3845 mL	11.9224 mL	23.8447 mL
5 mM	0.4769 mL	2.3845 mL	4.7689 mL
10 mM	0.2384 mL	1.1922 mL	2.3845 mL
50 mM	0.0477 mL	0.2384 mL	0.4769 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). *Expert Opin Investig Drugs*. 2019 Nov;28(11):1003-1012.

Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. *J Biomed Sci*. 2020 Jan 6;27(1):18.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481